Group 1 - Yuyue Medical has experienced a decline in stock price for five consecutive trading days, with a cumulative drop of -3.42% [1] - Founded in 1998, Yuyue Medical is committed to providing world-leading medical device products and service solutions across ten healthcare fields, including respiratory therapy, diabetes management, in vitro diagnostics, infection control, and emergency care [1] - Hu Jie's management of the Huabao CSI Medical ETF has seen a reduction in holdings of Yuyue Medical in the first quarter of this year [1] Group 2 - The Huabao CSI Medical ETF has a year-to-date return of 3.03%, ranking 1168 out of 3428 in its category [2] - The ETF's performance over various periods includes a near-term increase of 1.05% over the past week and a decrease of -2.83% over the past three months [2] - The ETF's performance is compared to the average of its peers, which shows a year-to-date return of 3.17% [2] Group 3 - Hu Jie, the fund manager of Huabao CSI Medical ETF, has a background in finance and has been with Huabao Fund Management since June 2006, holding various positions [3][4] - Hu Jie has managed multiple funds, including the Huabao CSI Medical Index Fund and has a cumulative management experience of over 12 years [4] - Huabao Fund Management was established in March 2003 and is led by Chairman Huang Kongwei and General Manager Xiang Hui [4]

Core Viewpoint - Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (Yuwell Medical) is committed to advancing high-quality healthcare through technological innovation and sustainable development, focusing on enhancing corporate governance and social responsibility [1][2]. Group 1: Company Overview - Yuwell Medical specializes in the research, development, production, sales, and service of medical equipment, maintaining a strong position in technological innovation with multiple R&D centers globally [2][3]. - The company has achieved significant technological advancements, particularly in emergency medical care and chronic disease management, contributing to healthcare solutions worldwide [2][3]. Group 2: Technological Innovation - Yuwell Medical has increased R&D investment to reshape medical devices, leveraging independent and collaborative research to enhance innovation capabilities [2][3]. - The company has developed advanced products such as continuous glucose monitoring systems and sleep apnea therapy devices, integrating artificial intelligence and digital technologies into operations [1][2]. Group 3: Sustainability and ESG Management - Yuwell Medical emphasizes environmental, social, and corporate governance (ESG) as a key driver for compliance management and high-quality development, actively engaging stakeholders and enhancing communication [3][4]. - The company has established a comprehensive EHS (Environment, Health, and Safety) management system, achieving a 100% completion rate for annual energy management targets [1][3]. Group 4: Corporate Governance - The corporate governance structure includes a General Meeting of Shareholders, a Board of Directors, and specialized committees, ensuring effective checks and balances and adherence to regulatory requirements [7][8]. - Yuwell Medical promotes board diversity, with 44.4% of directors being female, and emphasizes ethical integrity and leadership credibility in its governance practices [8][9]. Group 5: Financial Performance - The company reported a pass yield of 99.72% and high customer satisfaction rates of 97.2% for B2B clients and 97.7% for B2C users, indicating strong operational performance [1][2]. - Yuwell Medical's global operations span over 100 countries, contributing to its diversified product portfolio and market competitiveness [2][3].

1 Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. CONTENTS 33 Innovation-Driven Development: Empowering Life Through Technology 59 People-Centered Approach: Safeguarding Lives and Empowering People 81 Environmental Friendliness: Creating a Shared Green Future Reducing Environmental Impact 91 2 3 01 Message from the Chairman 03 About Yuwell Medical 05 Sustainable Development Management 11 Steady and Long-Term Progress: Advancing Towards High-Quality Development Enhancing Corporate Governance 13 Adherence ...

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in various time frames [1] - The latest net value of the fund is 2.7270 yuan, with a growth of 1.79% [1] - The fund's performance over the past month has yielded a return of 8.91%, ranking 96 out of 1025 in its category [1] - Over the last six months, the fund has achieved a return of 13.01%, ranking 146 out of 989 [1] - Year-to-date, the fund has returned 19.66%, ranking 96 out of 999 [1] Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant positions in companies such as Heng Rui Pharmaceutical (8.90%) and WuXi AppTec (5.12%) [1] - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

Core Insights - The medical device market in China and globally is experiencing steady growth driven by technological advancements and increasing health management needs [1][3] - Yuyue Medical is committed to long-term strategies and expanding its global presence while solidifying its domestic market foundation [1][3] Financial Performance - In 2024, Yuyue Medical reported total revenue of 7.566 billion and a net profit of 1.806 billion, showcasing strong performance [3] - Key business segments generated significant revenue: respiratory treatment solutions at 2.597 billion, blood glucose management at 1.03 billion, and home health testing solutions at 1.564 billion [3] Business Development - Yuyue Medical is focusing on innovation in respiratory treatment products, enhancing stability, noise reduction, lightweight design, and smart technology [3][4] - The company is advancing its blood glucose management and POCT business with a focus on CGM products, achieving breakthroughs in clinical accuracy and smart management [4] - The home health testing segment is also growing, with new product developments like the S series atrial fibrillation blood pressure monitor [6] Global Expansion Strategy - Yuyue Medical is actively expanding its global market presence, with overseas revenue reaching 949 million, a year-on-year increase of 30.42% [6][7] - The company is establishing subsidiaries and offices in countries like Thailand and Germany to enhance local market engagement and operational efficiency [7] - In 2024, Yuyue Medical obtained 103 overseas registration certificates, facilitating its international business growth [7] Future Outlook - The company expresses confidence in its future growth, driven by strong performance in key sectors and a dual-circulation strategy [6][9] - Yuyue Medical aims to leverage technological breakthroughs and global healthcare demand to expand its reach and impact [9]

Core Viewpoint - Increasingly, Chinese companies with a global vision, advanced technology, compliant operations, and high-quality products are emerging in the internationalization process, showcasing their international influence, particularly in the medical device sector, with companies like United Imaging and Mindray accelerating their overseas expansion [1][3]. Group 1: Market Impact - Following recent news, shares of major medical device companies faced pressure, with United Imaging (688271.SH) dropping nearly 6%, Mindray (300760.SZ) down nearly 2%, and Yuyue Medical (002223.SZ) falling nearly 3% [1]. - The European Union plans to impose restrictive measures on Chinese enterprises under the "International Procurement Instrument," potentially limiting their participation in EU public tender projects for medical devices valued over 5 million euros in the next five years [1][3]. Group 2: Industry Growth - The global medical device industry is rapidly developing, characterized by active trade and high product added value, providing significant opportunities for Chinese medical device companies to expand internationally [3]. - Chinese medical device exports are shifting from low-value products to a growing number of innovative devices entering overseas markets, indicating a move towards higher-end products in the industry [3][4]. Group 3: Innovation and Quality - High-quality clinical data is essential for gaining global market recognition, as demonstrated by a Shanghai-developed transcatheter aortic valve system that achieved significant clinical milestones, offering new treatment options for millions of patients [4]. - The Chinese medical device sector is transitioning from "Made in China" to "Intelligent Manufacturing in China," with products meeting international clinical standards and defining new treatment paradigms globally [4]. - Chinese companies are leading innovation in the global medical device field, with some products and technologies reaching a level of global originality and strong competitiveness, making them indispensable in the market [4].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The PD-1 (PD-L1)/VEGF dual antibody concept is gaining significant attention, with Chinese innovative pharmaceutical companies leading the research and development efforts [2][20]. - The global market for dual antibodies is projected to exceed $80 billion by 2030, with PD-1 (PD-L1)/VEGF drugs expected to challenge traditional PD-1/PD-L1 therapies in cancer treatment [20][21]. - The report highlights the importance of clinical data barriers and international expansion for companies in this sector, suggesting that these factors will create differentiated investment opportunities [3][26]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points [11][12]. - Among sub-industries, other biological products led with a 4.65% increase, while offline pharmacies saw a decline of 2.69% [12][19]. Clinical Progress - Notable advancements include the IND applications for BG-60366 by BeiGene and RFUS-949 by Renfu Pharmaceutical, as well as ongoing clinical trials for several drugs [29][30]. - Companies like Hengrui Medicine and Shijiazhuang Yiling Pharmaceutical are in Phase III trials, while others are in earlier stages [29][31]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [4][26]. - Key recommendations include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [4]. Company Updates - Recent announcements include significant collaborations and product approvals, such as the $60.5 billion global licensing deal between 3SBio and Pfizer [2][28]. - The report notes that as of June 1, 2025, there are 14 PD-1 (PD-L1)/VEGF products in clinical stages, all associated with Chinese companies [21][24].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The PD-1 (PD-L1)/VEGF dual antibody concept is gaining significant attention, with Chinese innovative pharmaceutical companies leading the research and development efforts [2][20]. - The global market for dual antibodies is projected to exceed $80 billion by 2030, with PD-1 (PD-L1)/VEGF drugs expected to challenge the traditional PD-1/PD-L1 drugs in cancer treatment [20][21]. - The report highlights the importance of clinical data barriers and international expansion for companies in this sector, suggesting that these factors will create differentiated investment opportunities [3][26]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 2.21%, outperforming the CSI 300 index by 3.30 percentage points and the ChiNext index by 2.00 percentage points, ranking second among 31 sub-industries [11][12]. Clinical Progress - Notable advancements include the IND applications for BG-60366 by BeiGene and RFUS-949 by Renfu Pharmaceutical, as well as ongoing clinical trials for various drugs by companies like Hengrui Medicine and Stone Pharmaceutical [29][30]. Key Developments - The report notes that 14 PD-1 (PD-L1)/VEGF products are currently in clinical stages, all associated with Chinese companies, with the fastest progress seen in Ivonescimab by Kangfang Biotech, which has been approved in China [21][22]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [4][26]. - Recommended companies include Hengrui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [4]. Company Announcements - Recent announcements include various companies receiving approvals for new drugs and medical devices, indicating ongoing innovation and regulatory progress within the sector [28][29].

Core Viewpoint - The article discusses the performance and holdings of the ICBC Frontier Medical Stock C fund, highlighting its recent growth and ranking among similar funds [1]. Fund Performance - The latest net value of ICBC Frontier Medical Stock C is 2.9850 yuan, reflecting a growth of 3.36% [1]. - The fund's return over the past month is 5.06%, ranking 72 out of 1022 similar funds [1]. - Over the last three months, the return is 10.06%, with a ranking of 63 out of 1009 [1]. - Year-to-date, the fund has achieved a return of 12.46%, ranking 107 out of 999 [1]. Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock C account for a total of 59.05% of the fund, with the following key positions: - Heng Rui Medicine: 10.11% - Kelun Pharmaceutical: 8.01% - WuXi AppTec: 7.72% - BeiGene: 6.85% - Xinlitai: 4.90% - Zai Lab: 4.77% - Yuyue Medical: 4.60% - New Horizon: 4.36% - East China Pharmaceutical: 4.20% - Haizhi Pharmaceutical: 3.53% [1]. Fund Background - ICBC Frontier Medical Stock C was established on November 23, 2020, and as of March 31, 2025, it has a total scale of 1.38 billion yuan [1]. - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2].